Wishing All Our Readers, Sponsors, Advertisers, Listers A Happy And Prosperous Chinese New Year 2020

BREAKING NEWS
Pharma News
Source: Thailand Medical News  Jan 18, 2020
Sales figures for the first cannabis-based medicine in the United States are in and they’re telling a bullish story, according to GW Pharmaceuticals CEO Justin Gover. The drug, Epidiolex, which contains cannabidiol to treat severe forms of epilepsy, brought in $104 million in net sales in the fourth quarter and a total of $296 million in 2019 across the globe, the British pharma...
Source: Thailand Medical News  Jan 17, 2020
The pharmaceutical news and media segment is abuzzed about a new development that will disrupt the way that individuals with allergies or reactions having anaphylaxis episodes are treated or able to treat themselves. A privately held Raleigh medical device company called Bryn Pharma, is on track to soon provide people who have severe, possibly life-threatening allergies a needle-free option t...
Source: Thailand Medical News  Jan 08, 2020
Galen Pharma, a Northern Ireland-based, globally focused pharmaceutical sales and marketing firm has acquired Swedish-headquartered POA Pharma in a multi-million pound takeover agreement. This takeover allows Galen to expand its global footprint further into Scandinavia and Northern Europe. POA Pharma has offices and facilities in Denmark, Sweden, Norway and Finland. The buy out will also broad...
Source: Thailand Medical News  Jan 06, 2020
Pharma giant, Merck also  known as MSD outside the United States and Canada, has announced an exclusive worldwide research collaboration and license agreement with Taiho Pharmaceutical Co, Ltd., (“Taiho”) and Astex Pharmaceuticals (UK), a wholly owned subsidiary of Otsuka Pharmaceutical Co., Ltd. (“Astex”), focused on the development of small molecule inhibitors agains...
Source: Thailand Medical News   Dec 26, 2019
Pharma Industry News Roche and Sarepta have signed a legal deal providing Roche exclusive commercial rights to SRP-9001 (AAVrh74.MHCK7.micro-dystrophin), Sarepta’s investigational gene therapy for Duchenne muscular dystrophy (DMD), outside the United States. Under the terms of the deal, Sarepta will receive US$1.15 billion in an upfront payment and an equity investment; up to $1.7 billion ...
Source: Thailand Medical News  Dec 21, 2019
Novartis, the Swiss pharmaceutical company is preparing to give away 100 doses of the world's most expensive drug, which treats a rare childhood disorder, through a special recipient selection process. The pharmaceutical giant announced this week that starting next month, its AveXis unit will begin distributing doses of Zolgensma, a one-time gene treatment for spinal muscular atrophy, also ...
Source: Thailand Medical news  Dec 17, 2019
Pharmaceuticals giant Roche said it had received the necessary approval from competition authorities to acquire US gene-therapy group Spark, after the two companies reached a multibillion-dollar deal earlier this year. Incorporated in 2013, Spark Therapeutics specialises in a new and growing segment of medicine for genetic diseases such as blindness, haemophilia, and neurodegenerative...
Source: Thailand Medical Newss  Dec 11, 2019
Pharma giant Roche has announced that it is terminating its precision medicine partnership with software developer Syapse later this month, the pharmaceutical and diagnostics giant confirmed Friday. The deal will end Dec. 18, less than two years after it began, a company spokesperson said. Roche spokesperson Patrick Barth told Thailand Medical News,  "As partnerships evolve, prioritie...
Source: Thailand Medical News  Dec 11, 2019
It was announced that AstraZeneca will partner with DeepMatter to improve the productivity and reproducibility of compound synthesis by combining the pharma giant’s automated compound synthesis platform with DeepMatter’s DigitalGlassware™ data collection and structuring technology, through a collaboration whose value was not disclosed. Glasgow based DeepMatter,is a big data and ...
Source: Thailand Medical News  Dec 10, 2019
Pharma News The global HIV specialists pharma company, ViiV Healthcare, majority owned by GSK, with Pfizer and Shionogi Limited as shareholders, has filed a New Drug Application in the US for fostemsavir, an investigational, first-in-class attachment inhibitor for the treatment of HIV-1 infection. Fostemsavir, the drug is being developed for use in combination with other antiretroviral agents ...
Source: Thailand Medical News  Dec 10, 2019
Pharma News The American Regulator,  the Food and Drug Administration (FDA) has approved the first generic versions of Novartis multiple sclerosis drug Gilenya (fingolimod).   Applications for the generic fingolimod by HEC Pharm, Biocon and Sun Pharmaceutical Industries secured the FDA authorisation to treat adults with relapsing forms of multiple sclerosis.   Multiple sclerosis ...
Source: Thailand Medical News  Dec 02, 2019
Biopharmaceutical company Incyte has announced that the US Food and Drug Administration (FDA) accepted for priority review its New Drug Application (NDA) for pemigatinib as a treatment for patients with cholangiocarcinoma.   Typically, Cholangiocarcinoma is cancer that forms in the bile duct, with patients often diagnosed at a late or advanced stage.   The drug Pemigatinib is a selecti...
Source: Thailand Medical News  Dec 02, 2019
Many big pharma and biotech conglomerates are going through a tough time. As businesses struggles, significant debt and legal liabilities put some industry players at particularly high risk of declaring bankruptcy in the near future, including large drugmakers like Teva Pharmaceutical and Bausch Health as well as small biotechs including Clovis Oncology and Puma Biotechnology. A pharma industry...
Source: Thailand Medical News  Nov 27, 2019
Bempedoic acid is an oral, once-daily ATP citrate lyase (ACL) inhibitor that reduces cholesterol synthesis in the liver and is currently undergoing regulatory review Bempedoic acid lowered LDL-Cholesterol by 17% on top of maximally-tolerated statin therapy at 12 weeks, and the effect was durable through 52 weeks1 Overall adverse events in the bempedoic acid treatment arm were comparable to pla...